Comparative Pharmacology
Head-to-head clinical analysis: ABSORICA versus TRETINOIN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ABSORICA versus TRETINOIN.
ABSORICA vs TRETINOIN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Isotretinoin is a retinoid that binds to nuclear retinoic acid receptors (RARs) and retinoid X receptors (RXRs), modulating gene expression involved in cell differentiation, proliferation, and apoptosis. It reduces sebaceous gland size and sebum production, inhibits sebocyte differentiation, and has anti-inflammatory effects.
Retinoic acid receptor agonist; binds to RAR and RXR nuclear receptors, modulating gene transcription involved in cell differentiation, proliferation, and apoptosis.
0.5-1 mg/kg/day orally in 2 divided doses for 15-20 weeks, then 0.1-0.5 mg/kg/day as maintenance.
Acute promyelocytic leukemia (APL): 45 mg/m2/day orally divided twice daily, as induction therapy.
None Documented
None Documented
Clinical Note
moderateTretinoin + Digoxin
"Tretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateAlitretinoin + Digoxin
"Alitretinoin may decrease the cardiotoxic activities of Digoxin."
Clinical Note
moderateTretinoin + Digitoxin
"Tretinoin may decrease the cardiotoxic activities of Digitoxin."
Clinical Note
moderateAlitretinoin + Digitoxin
"Alitretinoin may decrease the cardiotoxic activities of Digitoxin."
Terminal elimination half-life: 21-29 hours in adults; 33 hours in pediatric patients. Steady-state reached in 7-10 days.
Terminal elimination half-life is 0.5-2 hours for the parent drug, but may be prolonged to 10-12 hours after multiple dosing due to reduced clearance; clinical context: t1/2 is short, requiring frequent or continuous dosing to maintain therapeutic levels.
Renal (approx. 65% as metabolites) and biliary (approx. 35% as metabolites). Less than 1% excreted unchanged.
Primarily fecal (approx. 60%) via biliary excretion as metabolites; renal excretion accounts for <15% of a dose as unchanged drug and metabolites.
Category C
Category D/X
Retinoid
Retinoid